Table 1.
Clinical features and treatment outcomes in American, German, and Japanese patients with autoimmune hepatitis with and without antibodies to soluble liver antigen/liver pancreas (SLA/LP) antigen
| USA | Germany | Japan | ||||
| SLA/LP positive (n=23) | SLA/LP negative (n=126) | SLA/LP positive (n=21) | SLA/LP negative (n=87) | SLA/LP positive (n=2) | SLA/LP negative (n=28) | |
| AST (U/ml) | 442 (78) | 507 (37) | 186 (47) | 275 (27) | 51 (15.5) | 227 (62) |
| γ-globulins† | 3.1 (0.2) g/dl | 3.1 (0.1) g/dl | 27 (1.6) % | 31 (1)% | 34 (2)% | 30 (1.9)% |
| Bilirubin (mg/dl) | 4.9 (1.20) | 4.1 (0.5) | 3.4 (1.5) | 3.6 (0.6) | 0.8 (0.4) | 2.5 (0.6) |
| Age at diagnosis (y) | 43 (2) | 46 (2) | 41 (3) | 46 (2) | 48 (4) | 54 (3.1) |
| Sex (M:F) | 5:18 | 26:100 | 2:19 | 11:76 | 0:2 | 2:26 |
| Cirrhosis at diagnosis | 7/23 (30%) | 33/124 (27%) | 8/20 (40%) | 27/71 (38%) | 0 | na |
| Remission | 15/22 (68%) | 88/121 (73%) | 21 (100%) | 67/81 (83%) | na | na |
| Relapse after remission | 15/15 (100%)* | 64/88 (73%)* | 11/20 (55%)* | 28/82 (34%) * | na | na |
| Duration of symptoms (months) | 38 (11) | 27 (4) | 35 (9) | 26 (10) | na | na |
*Statistical difference between SLA/LP positive (26 of 35) and SLA/LP negative (92 of 170) at p=0.02.
†Units in US patients in g/dl, in German and Japanese patients as relative per cent (%) of total serum protein (absolute values not available in all patients).
AST, aspartate aminotransferase; na, not available.
Values are mean (SEM) or number (%).